Myriad Genetics (MYGN) Tops Q4 EPS by 6c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.57 --0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
SICP, MNSB, CFFI, More
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.06 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $209.8 million versus the consensus estimate of $207.17 million.
GUIDANCE:
Myriad Genetics sees Q1 2026 revenue of $200-203 million, versus the consensus of $211.3 million.
Myriad Genetics sees FY2026 revenue of $860-880 million, versus the consensus of $869.5 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spotify (SPOT) Misses Q3 EPS by 36c; misses on guidance
- TTM Technologies (TTMI) Tops Q3 EPS by 20c ; Offers Guidance
- Integra LifeSciences (IART) PT Lowered to $22 at Citizens on Specialty Surgical Business Headwinds
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
